Novavax Announces COVID-19 Vaccine Clinical Development Progress
The Pharma Data
NOVEMBER 30, 2020
These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (SEC).
Let's personalize your content